Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-FACT: Platform for Early Breast Cancer
NCT06535893Phase 2Recruiting
- Sponsor
- Nagoya City University
- Start
- Jul 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib in triple-negative breast cancer (TNBC), sponsored by Nagoya City University. Started Jul 2024; status: recruiting.
02
Drugs
niraparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06535893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06535893.